Treatment options for recurrent glioblastoma: pitfalls and future trends

被引:25
作者
Franceschi, Enrico [1 ]
Tosoni, Alicia [1 ]
Bartolini, Stefania [1 ]
Mazzocchi, Valeria [1 ]
Fioravanti, Antonio [2 ]
Brandes, Alba A. [1 ]
机构
[1] Bellaria Maggiore Hosp, Azienda USL Bologna, Dept Med Oncol, Bologna, Italy
[2] Bellaria Maggiore Hosp, Azienda USL Bologna, Dept Neurosurg, Bologna, Italy
关键词
glioblastoma; radiotherapy; recurrent; target therapy; temozolomide; PHASE-II TRIAL; POSITRON-EMISSION-TOMOGRAPHY; MALIGNANT GLIOMA PATIENTS; GROWTH-FACTOR RECEPTOR; BRAIN-TUMOR; CONCOMITANT RADIOCHEMOTHERAPY; 2ND-LINE CHEMOTHERAPY; TEMOZOLOMIDE; IRINOTECAN; PLUS;
D O I
10.1586/ERA.09.23
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Standard treatment with temozolomide and radiotherapy for patients with newly diagnosed glioblastoma has increased the median overall survival and, more importantly, the 2-year survival rate of patients. However, as yet, no investigations have been conducted to define effective strategies against recurrence, which occurs in most patients following combined radiotherapy/temozolomide treatment. Furthermore, in recent years, new issues have emerged regarding the evaluation of disease response, and also with the identification of patterns such as pseudoprogression, frequently indistinguishable from real disease progression. New therapeutic strategies, such as targeted therapies and anti-angiogenic treatments that appear promising with regard to improving the results at the time of recurrence are discussed.
引用
收藏
页码:613 / 619
页数:7
相关论文
共 56 条
[51]   Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery - In malignant glioma [J].
Tsuyuguchi, N ;
Takami, T ;
Sunada, I ;
Iwai, Y ;
Yamanaka, K ;
Tanaka, Y ;
Nishikawa, M ;
Ohata, K ;
Torii, K ;
Morino, M ;
Nishio, A ;
Hara, M .
ANNALS OF NUCLEAR MEDICINE, 2004, 18 (04) :291-296
[52]   Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034 [J].
van den Bent, Martin J. ;
Brandes, Alba A. ;
Rampling, Roy ;
Kouwenhoven, Mathilde C. M. ;
Kros, Johan M. ;
Carpentier, Antoine F. ;
Clement, Paul M. ;
Frenay, Marc ;
Campone, Mario ;
Baurain, Jean-Francois ;
Armand, Jean-Paul ;
Taphoorn, Martin J. B. ;
Tosoni, Alicia ;
Kletzl, Heidemarie ;
Klughammer, Barbara ;
Lacombe, Denis ;
Gorlia, Thierry .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) :1268-1274
[53]   Bevacizumab plus irinotecan in recurrent glioblastoma multiforme [J].
Vredenburgh, James J. ;
Desjardins, Annick ;
Herndon, James E., II ;
Marcello, Jennifer ;
Reardon, David A. ;
Quinn, Jennifer A. ;
Rich, Jeremy N. ;
Sathornsumetee, Sith ;
Gururangan, Sridharan ;
Sampson, John ;
Wagner, Melissa ;
Bailey, Leighann ;
Bigner, Darell D. ;
Friedman, Allan H. ;
Friedman, Henry S. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) :4722-4729
[54]   Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma [J].
Vredenburgh, James J. ;
Desjardins, Annick ;
Herndon, James E., II ;
Dowel, Jeannette M. ;
Reardon, David A. ;
Quinn, Jennifer A. ;
Rich, Jeremy N. ;
Sathornsumetee, Sith ;
Gururangan, Sridharan ;
Wagner, Melissa ;
Bigner, Darell D. ;
Friedman, Allan H. ;
Friedman, Henry S. .
CLINICAL CANCER RESEARCH, 2007, 13 (04) :1253-1259
[55]   Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials [J].
Wong, ET ;
Hess, KR ;
Gleason, MJ ;
Jaeckle, KA ;
Kyritsis, AP ;
Prados, MD ;
Levin, VA ;
Yung, WKA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2572-2578
[56]  
YOUNG B, 1981, J NEUROSURG, V55, P917, DOI 10.3171/jns.1981.55.6.0917